| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1128 | 2013 |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 920 | 2017 |
| Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma AKA Lalani, W Xie, DJ Martini, JA Steinharter, CK Norton, KM Krajewski, ... Journal for immunotherapy of cancer 6, 1-9, 2018 | 260 | 2018 |
| The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients PS Hall, LC Harshman, S Srinivas, RM Witteles JACC: Heart Failure 1 (1), 72-78, 2013 | 233 | 2013 |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ... Cancer 121 (15), 2586-2593, 2015 | 197 | 2015 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 164 | 2019 |
| Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) E Francini, KP Gray, W Xie, GK Shaw, L Valença, B Bernard, L Albiges, ... The Prostate 78 (12), 889-895, 2018 | 163 | 2018 |
| Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey SL Chang, LC Harshman, JC Presti Jr Journal of clinical oncology 28 (25), 3951-3957, 2010 | 156 | 2010 |
| Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer LC Harshman, X Wang, M Nakabayashi, W Xie, L Valenca, L Werner, ... JAMA oncology 1 (4), 495-504, 2015 | 154 | 2015 |
| Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study LC Harshman, W Xie, GA Bjarnason, JJ Knox, M MacKenzie, L Wood, ... The lancet oncology 13 (9), 927-935, 2012 | 142 | 2012 |
| Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features BA McGregor, RR McKay, DA Braun, L Werner, K Gray, A Flaifel, ... Journal of Clinical Oncology 38 (1), 63-70, 2020 | 140 | 2020 |
| Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder T Seisen, M Sun, SR Lipsitz, F Abdollah, JJ Leow, M Menon, MA Preston, ... European urology 72 (4), 483-487, 2017 | 135 | 2017 |
| Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites AH Nassar, R Umeton, J Kim, K Lundgren, L Harshman, EM Van Allen, ... Clinical Cancer Research 25 (8), 2458-2470, 2019 | 126 | 2019 |
| Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone RR McKay, H Ye, W Xie, R Lis, C Calagua, Z Zhang, QD Trinh, SL Chang, ... Journal of Clinical Oncology 37 (11), 923-931, 2019 | 126 | 2019 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 122 | 2021 |
| The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma RR McKay, D Bossé, W Xie, SAM Wankowicz, A Flaifel, R Brandao, ... Cancer immunology research 6 (7), 758-765, 2018 | 122 | 2018 |
| Tumor fraction in cell-free DNA as a biomarker in prostate cancer AD Choudhury, L Werner, E Francini, XX Wei, G Ha, SS Freeman, ... JCI insight 3 (21), 2018 | 120 | 2018 |
| Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel LC Harshman, YH Chen, G Liu, MA Carducci, D Jarrard, R Dreicer, ... Journal of Clinical Oncology 36 (4), 376-382, 2018 | 114 | 2018 |
| Adjuvant vascular endothelial growth factor–targeted therapy in renal cell carcinoma: a systematic review and pooled analysis M Sun, L Marconi, T Eisen, B Escudier, RH Giles, NB Haas, LC Harshman, ... European urology 74 (5), 611-620, 2018 | 105 | 2018 |
| Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and … J Sharma, KP Gray, LC Harshman, C Evan, M Nakabayashi, R Fichorova, ... The Prostate 74 (8), 820-828, 2014 | 102 | 2014 |
